Will marijuana be rescheduled?
Short Answer
The model assigns meaningfully higher odds than the market for marijuana being rescheduled Before Jan 20, 2029 (96.6% model vs 84.0% market). This divergence is driven by the Department of Justice's official announcement that marijuana products were placed into Schedule III, fulfilling the condition of being lowered from Schedule I.
1. Executive Verdict
- DOJ announced marijuana products were lowered to Schedule III on April 23, 2026.
- Trump's 2025 Executive Order directed expeditious rescheduling to Schedule III.
- Schedule III rescheduling offers significant commercial and financial benefits.
- Public comments overwhelmingly indicate support for broader cannabis reform.
- Market probability spiked 11 percentage points on April 26, 2026.
Who Wins and Why
| Outcome | Market | Model | Why |
|---|---|---|---|
| Before July 2026 | 2.5% | 22.0% | The Department of Justice officially announced marijuana's rescheduling to Schedule III on April 23, 2026. |
| Before 2027 | 35.0% | 47.1% | The Department of Justice officially announced marijuana's rescheduling to Schedule III on April 23, 2026. |
| Before 2028 | 81.0% | 92.8% | The Department of Justice officially announced marijuana's rescheduling to Schedule III on April 23, 2026. |
| Before Jan 20, 2029 | 84.0% | 96.6% | The Department of Justice officially announced marijuana's rescheduling to Schedule III on April 23, 2026. |
Current Context
Recent executive and departmental actions have expedited marijuana's rescheduling process. An Executive Order signed by President Trump on December 18, 2025, directed the expedited rescheduling of marijuana to Schedule III [^][^][^]. Subsequently, on April 23, 2026, the Department of Justice (DOJ) issued an order by Acting Attorney General Todd Blanche [^][^][^][^]. This order officially placed FDA-approved marijuana products and those containing marijuana subject to a qualifying state-issued license into Schedule III, effective April 22, 2026 [^][^][^][^].
While medical marijuana moved to Schedule III, recreational cannabis remains restricted. Despite the reclassification for medical cannabis, recreational cannabis continues to be classified as Schedule I, with no federal legalization enacted [^][^][^][^]. A hearing for broader cannabis rescheduling is scheduled to occur between June 29 and July 15, 2026 [^][^][^].
Rescheduling offers significant advantages for medical cannabis research and industry. This reclassification is expected to ease existing barriers for scientific research into marijuana [^][^][^]. Furthermore, qualifying businesses in the cannabis industry will now be able to utilize 280E tax deductions, and improved access to banking services is anticipated [^][^][^].
2. Market Behavior & Price Dynamics
Historical Price (Probability)
Outcome probability
Date
This market has exhibited a sideways trend, trading within a narrow range between a support level of 1.6% and a resistance level of 10.0%. The price opened at 3.1% and is currently at 2.5%, indicating minimal net change and a lack of directional conviction over the market's lifetime. Despite the significant total volume traded, recent volume has been extremely low, as seen in the sample data points. This suggests that while there was initial interest, the market has since entered a period of low activity, with traders seeing little new information to justify re-evaluating the odds. The market's stability implies a consensus has been reached at these low probability levels.
The price action suggests that the significant news events occurred prior to or right at the beginning of active trading. An Executive Order was reported to have been signed on December 18, 2025, and a subsequent DOJ order was issued on April 23, 2026, both actions aimed at expediting the rescheduling process. The market's sample data begins on April 26, 2026, after these events were public knowledge. Consequently, the market price never reacted to this news with a spike; instead, it opened at a low probability and has remained there. This indicates that traders have already priced in these administrative actions.
The persistently low probability, currently at 2.5%, signals strong market skepticism that the rescheduling process will be fully completed to satisfy the market's resolution criteria. Despite the executive push, traders are assigning a very low chance of a final, successful rescheduling. The combination of a flat trend, low current price, and diminished recent volume suggests the market believes the outcome is largely settled as a NO, and it would require substantial, unforeseen developments to shift this sentiment.
3. Significant Price Movements
Notable price changes detected in the chart, along with research into what caused each movement.
📈 April 26, 2026: 11.0pp spike
Price increased from 72.0% to 83.0%
Outcome: Before 2028
What happened: The primary driver of the prediction market price movement was the formal announcement by Acting Attorney General Todd Blanche on April 22-23, 2026, that FDA-approved and state medical marijuana products would be immediately rescheduled from Schedule I to Schedule III [^][^][^][^]. This official policy action, stemming from a December 2025 Trump executive order, significantly advanced the likelihood of marijuana rescheduling before 2028 [^][^][^]. The market spike on April 26, 2026, coincided with this news, causing cannabis stocks to surge then pull back, driving considerable volatility [^]. Social media was irrelevant as a primary driver, with the movement directly attributable to a major government policy decision.
4. Market Data
Contract Snapshot
For the "Before 2027" market, a YES resolution occurs if marijuana is legally moved from Schedule I to a lower drug schedule under the Controlled Substances Act before January 1, 2027, or if its schedule is ended entirely. A NO resolution occurs if this does not happen, or if only certain cannabis derivatives are rescheduled without reclassifying marijuana as a whole. The rescheduling must have taken legal effect and fully removed marijuana from Schedule I, not just been announced; the market closes by December 31, 2026, at 11:59 pm EST if the event doesn't occur beforehand.
Available Contracts
Market options and current pricing
| Outcome bucket | Yes (price) | No (price) | Last trade probability |
|---|---|---|---|
| Before July 2026 | $0.03 | $0.98 | 3% |
| Before 2027 | $0.36 | $0.65 | 35% |
| Before 2028 | $0.81 | $0.21 | 81% |
| Before Jan 20, 2029 | $0.85 | $0.16 | 84% |
Market Discussion
Traders are debating the strict interpretation of the market rules, specifically whether all cannabis will be moved off Schedule I to trigger a "Yes" resolution. Arguments for "No" highlight that some cannabis derivatives may remain on Schedule I and note procedural delays with hearings extending past deadlines. Conversely, "Yes" traders express confusion about why a payout hasn't occurred, believing that rescheduling should have already taken place via executive action.
5. What are the key arguments and potential administrative actions following the DEA's broader cannabis rescheduling hearing in mid-2026?
| Trump Executive Order Date | December 18, 2025 [^][^][^] |
|---|---|
| Partial Rescheduling Date | April 23, 2026 [^][^][^] |
| Broader Rescheduling Hearing Dates | June 29-July 15, 2026 [^][^][^] |
A 2025 Executive Order propelled recent cannabis rescheduling efforts. The impetus for broader cannabis rescheduling originated from a December 18, 2025, Executive Order, which mandated an expedited move to Schedule III and superseded an earlier administration's process [^][^][^]. This directive led to an initial, partial rescheduling on April 23, 2026, which reclassified FDA-approved and qualifying state medical marijuana products to Schedule III. However, recreational marijuana products continue to be classified under Schedule I [^][^][^].
A broader cannabis rescheduling hearing is scheduled for mid-2026. A hearing concerning broader cannabis rescheduling is slated for June 29 through July 15, 2026, in Arlington, VA. This proceeding will be presided over by an Administrative Law Judge appointed by Acting Attorney General Todd Blanche, with official notices anticipated between May 24 and May 28, 2026 [^][^][^].
Full rescheduling would mandate new federal regulatory requirements. Should full rescheduling be enacted subsequent to the hearing, new administrative requirements would necessitate DEA registrations for entities involved in manufacturing, distribution, and dispensing of cannabis products. A 60-day transition period would also be established for current state licensees to adapt to these federal regulations [^][^].
6. How does the standard rescheduling process under the Controlled Substances Act compare to the specific actions taken by the Trump administration's DOJ in 2025-2026?
| Executive Order Date | December 18, 2025 [^][^][^] |
|---|---|
| Rescheduling Order Effective Date | April 22-28, 2026 [^][^][^][^][^] |
| Odds for Full Rescheduling (by July 2026) | Approximately 10% [^] |
The Trump administration expedited marijuana rescheduling differently than the standard process. The standard rescheduling process under the Controlled Substances Act (CSA) typically involves the Drug Enforcement Administration (DEA) requesting a scientific evaluation and recommendation from the Department of Health and Human Services (HHS) and Food and Drug Administration (FDA), followed by notice-and-comment rulemaking and an eight-factor evaluation [^]. In contrast, the Trump administration's Department of Justice (DOJ) in 2025-2026 initiated its approach with an Executive Order on December 18, 2025. This order directed the DOJ to expedite marijuana's reclassification to Schedule III via 21 U.S.C. 811, a specific process that did not necessitate notice-and-comment rulemaking for this particular rescheduling [^][^][^][^].
A Final Order partially rescheduled marijuana, maintaining controls on other forms. An April 2026 Final Order, effective around April 22-28, formally moved FDA-approved marijuana products and marijuana subject to a qualifying state-issued medical license to Schedule III. This action leveraged treaty authority under 21 U.S.C. 811(d)(1) [^][^][^][^][^]. This targeted rescheduling, however, left recreational and unlicensed marijuana classified as Schedule I [^][^][^]. While this partial rescheduling was implemented, broader rescheduling hearings were set to begin on June 29, 2026 [^][^][^]. At the time, prediction markets indicated approximately 10% odds for a full rescheduling of marijuana before July 2026, distinguishing between the partial and comprehensive scope of these actions [^].
7. How do the legal and commercial impacts of rescheduling to Schedule III differ from full federal legalization for cannabis businesses?
| Tax Rate Reduction (Medical Cannabis) | From 60-70% to 25-30% (under Schedule III) [^][^][^][^] |
|---|---|
| Interstate Commerce (Rescheduling) | Not permitted [^][^][^][^][^] |
| Federal Legalization Impact | Enables national markets and standardized regulation [^][^][^][^][^] |
Rescheduling cannabis to Schedule III offers significant commercial benefits for medical cannabis businesses. This reclassification would exempt businesses from IRC Section 280E, allowing them to deduct ordinary operating expenses and consequently reducing effective tax rates from an estimated 60-70% to approximately 25-30% [^][^][^][^]. Banking access is also expected to improve due to a lower perceived risk profile [^][^][^][^]. However, this change does not permit interstate commerce for cannabis, nor does it federally legalize recreational cannabis, which would remain a Schedule I substance [^][^][^][^][^]. Furthermore, criminal penalties under the Controlled Substances Act for unauthorized possession or distribution would persist [^][^][^]. The Department of Justice has announced an April 2026 timeframe for placing medical cannabis in Schedule III, with a hearing on June 29, 2026, for additional reform [^][^].
Full federal legalization would establish national markets and end federal prohibitions. Descheduling cannabis entirely is necessary to create national markets and implement standardized federal regulations, which rescheduling to Schedule III does not accomplish [^][^][^][^][^]. Such a comprehensive change would fully remove federal prohibitions, enabling complete interstate commerce and potentially full banking access for all cannabis businesses, including those in the recreational sector [^][^][^][^][^][^][^][^]. The current rescheduling initiatives primarily target medical cannabis, thereby maintaining a separate legal and commercial landscape for recreational cannabis [^][^][^][^][^].
8. What does public comment data submitted to the DEA reveal about the primary arguments from industry, medical, and law enforcement stakeholders regarding rescheduling?
| Public comments favoring descheduling | 69.3% of 42,925 comments [^] |
|---|---|
| Physicians seeing medical value | 69% [^] |
| National Sheriffs’ Association stance | Opposes rescheduling to Schedule III [^] |
Public comments overwhelmingly favor broader cannabis reform. A significant majority, 69.3% of the 42,925 comments submitted to the DEA, expressed support for descheduling, decriminalization, or legalization of marijuana [^]. This issue has elicited distinct arguments from various stakeholders, including industry, medical groups, and law enforcement, concerning the proposed rescheduling [^][^][^][^].
Industry and medical groups advocate for rescheduling due to benefits. Industry stakeholders highlight a reported decrease in youth cannabis use and its potential as an opioid alternative, while also raising concerns about the economic burdens associated with Schedule I taxes [^]. Medical organizations, such as the Epilepsy Foundation, also support rescheduling, with a CDC survey indicating that 69% of physicians acknowledge marijuana's medical value [^].
Law enforcement presents divided opinions on cannabis rescheduling. The National Sheriffs’ Association (NSA) opposes rescheduling marijuana to Schedule III, instead suggesting Schedule II as its maximum classification [^]. Conversely, some police officers support rescheduling, citing practical considerations related to enforcement efforts [^].
9. What is the projected financial impact on state-licensed cannabis businesses from the removal of the 280E tax provision if rescheduling to Schedule III is finalized?
| Tax Rate Drop for Medical Cannabis Businesses | From over 70% to 25-30% [^][^][^][^] |
|---|---|
| Annual After-Tax Cash Flow Increase | $1.6–$2.2 billion [^] |
| Annual Tax Savings for Top MSOs | Over $700 million [^][^] |
Finalized Schedule III rescheduling promises significant financial relief for cannabis businesses. State-licensed medical cannabis businesses are projected to experience significant financial improvements if cannabis rescheduling to Schedule III is finalized. This benefit stems primarily from the removal of the 280E tax provision, which is expected to lower effective tax rates for qualifying medical cannabis businesses from over 70% to an estimated 25-30% [^][^][^][^].
The 280E repeal could generate substantial industry-wide cash flow. Across the industry, the removal of the 280E tax provision is estimated to generate an additional $1.6–$2.2 billion in after-tax cash flow annually [^]. Specifically, the 12 largest multi-state operators (MSOs) could save over $700 million annually in federal taxes [^][^]. Furthermore, MSOs currently owe $1.6 billion in 280E taxes, and rescheduling may enable refunds or relief for these past tax obligations [^].
10. What Could Change the Odds
Key Catalysts
A DEA hearing on full rescheduling is scheduled from 2026-06-29 to 2026-07-15 [^] [^] [^] [^] . Market odds from Kalshi in May 2026 indicate an 83% probability by 2029-01-20, 43% by 2027, and 7% by Jul 2026 [^][^]. Polymarket data shows a 36% probability by 2026-12-31 and 5% by 2026-06-30 [^]. A potential final rule is expected in late 2026 or 2027, which would be subject to litigation [^][^].
Key Dates & Catalysts
- Expiration: July 08, 2026
- Closes: January 20, 2029
11. Decision-Flipping Events
- Trigger: An Executive Order issued on 2025-12-18 by Trump directed expeditious rescheduling to Schedule III [^] [^] [^] [^] .
- Trigger: Subsequently, a DOJ/DEA order on 2026-04-23 placed FDA-approved and state medical marijuana in Schedule III immediately [^] [^] [^] .
- Trigger: A DEA hearing on full rescheduling is scheduled from 2026-06-29 to 2026-07-15 [^] [^] [^] [^] .
- Trigger: Market odds from Kalshi in May 2026 indicate an 83% probability by 2029-01-20, 43% by 2027, and 7% by Jul 2026 [^] [^] .
13. Related News
Last updated: May 10, 2026, 13:11 UTC
Marijuana Rescheduling Market Pushes Out Timeline After DOJ Action
Probabilities for a near-term, comprehensive federal rescheduling of marijuana fell sharply on Thursday, April 23, 2026, after the Department of Justice (DOJ) announced a final order that reclassified...
Last updated: May 10, 2026, 13:11 UTC
Marijuana Rescheduling Timeline Compresses Sharply on DOJ News
Prediction markets tracking the federal rescheduling of marijuana saw a sharp, positive repricing on Wednesday, April 22, 2026, as all contracts moved toward a significantly accelerated timeline. The ...
14. Historical Resolutions
No historical resolution data available for this series.
Get Real-Time Research Updates
Sign up for early access to live reports, historical data, and AI-powered market insights delivered to your inbox.
